{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T06:49:56Z","timestamp":1781246996435,"version":"3.54.1"},"reference-count":53,"publisher":"American Diabetes Association","issue":"10","license":[{"start":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T00:00:00Z","timestamp":1690329600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.diabetesjournals.org\/journals\/pages\/license"}],"funder":[{"DOI":"10.13039\/501100004040","name":"KU Leuven","doi-asserted-by":"crossref","award":["C1\/18\/006"],"award-info":[{"award-number":["C1\/18\/006"]}],"id":[{"id":"10.13039\/501100004040","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003130","name":"Research Foundation Flanders","doi-asserted-by":"crossref","award":["1.1A02.20N"],"award-info":[{"award-number":["1.1A02.20N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003130","name":"Research Foundation Flanders","doi-asserted-by":"crossref","award":["G.0C63.19N"],"award-info":[{"award-number":["G.0C63.19N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Hippo & Friends type 1 diabetes and Carpe Diem"}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,10,1]]},"abstract":"<jats:sec>\n                  <jats:title\/>\n                  <jats:p>Immunomodulation combined with antigen therapy holds great promise to arrest autoimmune type 1 diabetes, but clinical translation is hampered by a lack of prognostic biomarkers. Low-dose anti-CD3 plus Lactococcus lactis bacteria secreting proinsulin and IL-10 reversed new-onset disease in nonobese diabetic (NOD) mice, yet some mice were resistant to the therapy. Using miRNA profiling, six miRNAs (i.e., miR-34a-5p, miR-125a-3p, miR-193b-3p, miR-328, miR-365\u20133p, and miR-671\u20133p) were identified as differentially expressed in plasma of responder versus nonresponder mice before study entry. After validation and stratification in an independent cohort, plasma miR-193b-3p and miR-365\u20133p, combined with age and glycemic status at study entry, had the best power to predict, with high sensitivity and specificity, poor response to the therapy. These miRNAs were highly abundant in pancreas-infiltrating neutrophils and basophils with a proinflammatory and activated phenotype. Here, a set of miRNAs and disease-associated parameters are presented as a predictive signature for the L. lactis\u2013based immunotherapy outcome in new-onset type 1 diabetes, hence allowing targeted recruitment of trial participants and accelerated trial execution.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Article Highlights<\/jats:title>\n                  <jats:p>Low-dose anti-CD3 combined with oral gavage of genetically modified Lactococcus lactis bacteria secreting human proinsulin and IL-10 holds great promise to arrest autoimmune type 1 diabetes, but the absence of biomarkers predicting therapeutic success hampers clinical translation. A set of cell-free circulation miRNAs together with age and glycemia at baseline predicts a poor response after L. lactis\u2013based immunotherapy in nonobese mice with new-onset diabetes. Pancreas-infiltrating neutrophils and basophils are identified as potential cellular sources of discovered miRNAs. The prognostic signature could guide targeted recruitment of patients with newly diagnosed type 1 diabetes in clinical trials with the L. lactis\u2013based immunotherapy.<\/jats:p>\n               <\/jats:sec>","DOI":"10.2337\/db22-0852","type":"journal-article","created":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T20:26:12Z","timestamp":1690403172000},"page":"1470-1482","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":10,"title":["A Plasma miR-193b-365 Signature Combined With Age and Glycemic Status Predicts Response to <i>Lactococcus lactis<\/i>\u2013Based Antigen-Specific Immunotherapy in New-Onset Type 1 Diabetes"],"prefix":"10.2337","volume":"72","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7921-2764","authenticated-orcid":false,"given":"Gabriele","family":"Sassi","sequence":"first","affiliation":[{"name":"1Clinical and Experimental Endocrinology, Chrometa, KU Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giada","family":"Licata","sequence":"additional","affiliation":[{"name":"2Diabetes Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy"},{"name":"3Fondazione Umberto Di Mario ONLUS, Toscana Life Science, Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuliana","family":"Ventriglia","sequence":"additional","affiliation":[{"name":"2Diabetes Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy"},{"name":"3Fondazione Umberto Di Mario ONLUS, Toscana Life Science, Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amber","family":"Wouters","sequence":"additional","affiliation":[{"name":"1Clinical and Experimental Endocrinology, Chrometa, KU Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Lemaitre","sequence":"additional","affiliation":[{"name":"1Clinical and Experimental Endocrinology, Chrometa, KU Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Seurinck","sequence":"additional","affiliation":[{"name":"4Data Mining and Modelling for Biomedicine, VIB Center for Inflammation Research, Ghent, Belgium"},{"name":"5Department of Applied Mathematics, Computer Science and Statistics, Ghent University, Ghent, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Mori","sequence":"additional","affiliation":[{"name":"6Tuscany Centre for Precision Medicine, Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppina Emanuela","family":"Grieco","sequence":"additional","affiliation":[{"name":"2Diabetes Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy"},{"name":"3Fondazione Umberto Di Mario ONLUS, Toscana Life Science, Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samal","family":"Bissenova","sequence":"additional","affiliation":[{"name":"1Clinical and Experimental Endocrinology, Chrometa, KU Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darcy","family":"Ellis","sequence":"additional","affiliation":[{"name":"1Clinical and Experimental Endocrinology, Chrometa, KU Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Caluwaerts","sequence":"additional","affiliation":[{"name":"7Precigen ActoBio, Zwijnaarde (Ghent), Ghent, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter","family":"Rottiers","sequence":"additional","affiliation":[{"name":"7Precigen ActoBio, Zwijnaarde (Ghent), Ghent, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels","family":"Vandamme","sequence":"additional","affiliation":[{"name":"4Data Mining and Modelling for Biomedicine, VIB Center for Inflammation Research, Ghent, Belgium"},{"name":"8VIB Single Cell Core, Leuven\u2013Ghent, Ghent, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6099-2406","authenticated-orcid":false,"given":"Chantal","family":"Mathieu","sequence":"additional","affiliation":[{"name":"1Clinical and Experimental Endocrinology, Chrometa, KU Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4947-7478","authenticated-orcid":false,"given":"Francesco","family":"Dotta","sequence":"additional","affiliation":[{"name":"2Diabetes Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy"},{"name":"3Fondazione Umberto Di Mario ONLUS, Toscana Life Science, Siena, Italy"},{"name":"6Tuscany Centre for Precision Medicine, Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conny","family":"Gysemans","sequence":"additional","affiliation":[{"name":"1Clinical and Experimental Endocrinology, Chrometa, KU Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4374-8564","authenticated-orcid":false,"given":"Guido","family":"Sebastiani","sequence":"additional","affiliation":[{"name":"2Diabetes Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy"},{"name":"3Fondazione Umberto Di Mario ONLUS, Toscana Life Science, Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2023,7,26]]},"reference":[{"key":"2023092018510960700_B1","doi-asserted-by":"crossref","first-page":"e142242","DOI":"10.1172\/JCI142242","article-title":"Type 1 diabetes mellitus: much progress, many opportunities","volume":"131","author":"Powers","year":"2021","journal-title":"J Clin Invest"},{"key":"2023092018510960700_B2","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/s41574-019-0254-y","article-title":"The heterogeneous pathogenesis of type 1 diabetes mellitus","volume":"15","author":"Ilonen","year":"2019","journal-title":"Nat Rev Endocrinol"},{"key":"2023092018510960700_B3","doi-asserted-by":"crossref","first-page":"542","DOI":"10.3390\/jpm12040542","article-title":"Personalized immunotherapies for type 1 diabetes: who, what, when, and how?","volume":"12","author":"Deligne","year":"2022","journal-title":"J Pers Med"},{"key":"2023092018510960700_B4","doi-asserted-by":"crossref","first-page":"932086","DOI":"10.3389\/fmed.2022.932086","article-title":"From disease and patient heterogeneity to precision medicine in type 1 diabetes","volume":"9","author":"den Hollander","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"2023092018510960700_B5","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2337\/dc19-0880","article-title":"Introducing the endotype concept to address the challenge of disease heterogeneity in type 1 diabetes","volume":"43","author":"Battaglia","year":"2020","journal-title":"Diabetes Care"},{"key":"2023092018510960700_B6","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1056\/NEJMoa012864","article-title":"Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus","volume":"346","author":"Herold","year":"2002","journal-title":"N Engl J Med"},{"key":"2023092018510960700_B7","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1056\/NEJMoa043980","article-title":"Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes","volume":"352","author":"Keymeulen","year":"2005","journal-title":"N Engl J Med"},{"key":"2023092018510960700_B8","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s00125-020-05317-y","article-title":"A randomised, single-blind, placebo-controlled, dose-finding safety and tolerability study of the anti-CD3 monoclonal antibody otelixizumab in new-onset type 1 diabetes","volume":"64","author":"Keymeulen","year":"2021","journal-title":"Diabetologia"},{"key":"2023092018510960700_B9","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1056\/NEJMoa0904452","article-title":"Rituximab, B-lymphocyte depletion, and preservation of beta-cell function","volume":"361","author":"Pescovitz","year":"2009","journal-title":"N Engl J Med"},{"key":"2023092018510960700_B10","doi-asserted-by":"crossref","first-page":"3766","DOI":"10.2337\/db13-0345","article-title":"Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders","volume":"62","author":"Herold","year":"2013","journal-title":"Diabetes"},{"key":"2023092018510960700_B11","doi-asserted-by":"crossref","first-page":"eabc8980","DOI":"10.1126\/scitranslmed.abc8980","article-title":"Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals","volume":"13","author":"Sims","year":"2021","journal-title":"Sci Transl Med"},{"key":"2023092018510960700_B12","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/S2213-8587(13)70065-2","article-title":"Antithymocyte globulin treatment for patients with recent-onset type 1 diabetes: 12-month results of a randomised, placebo-controlled, phase 2 trial","volume":"1","author":"Gitelman","year":"2013","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2023092018510960700_B13","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.2337\/dc18-0494","article-title":"Low-dose anti-thymocyte globulin (ATG) preserves \u03b2-cell function and improves HbA1c in new-onset type 1 diabetes","volume":"41","author":"Haller","year":"2018","journal-title":"Diabetes Care"},{"key":"2023092018510960700_B14","doi-asserted-by":"crossref","first-page":"e053669","DOI":"10.1136\/bmjopen-2021-053669","article-title":"Study protocol: minimum effective low dose: anti-human thymocyte globulin (MELD-ATG): phase II, dose ranging, efficacy study of antithymocyte globulin (ATG) within 6 weeks of diagnosis of type 1 diabetes","volume":"11","author":"Wilhelm-Benartzi","year":"2021","journal-title":"BMJ Open"},{"key":"2023092018510960700_B15","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/S0140-6736(11)60886-6","article-title":"Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial","volume":"378","author":"Orban","year":"2011","journal-title":"Lancet"},{"key":"2023092018510960700_B16","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1089\/dia.2020.0305","article-title":"Comparing beta cell preservation across clinical trials in recent-onset type 1 diabetes","volume":"22","author":"Jacobsen","year":"2020","journal-title":"Diabetes Technol Ther"},{"key":"2023092018510960700_B17","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1097\/MED.0000000000000647","article-title":"Current state of antigen-specific immunotherapy for type 1 diabetes","volume":"28","author":"Kreiner","year":"2021","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"2023092018510960700_B18","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1172\/JCI60530","article-title":"Reversal of autoimmune diabetes by restoration of antigen-specific tolerance using genetically modified Lactococcus lactis in mice","volume":"122","author":"Takiishi","year":"2012","journal-title":"J Clin Invest"},{"key":"2023092018510960700_B19","doi-asserted-by":"crossref","first-page":"448","DOI":"10.2337\/db15-1625","article-title":"Reversal of diabetes in NOD mice by clinical-grade proinsulin and IL-10-secreting Lactococcus lactis in combination with low-dose anti-CD3 depends on the induction of Foxp3-positive T cells","volume":"66","author":"Takiishi","year":"2017","journal-title":"Diabetes"},{"key":"2023092018510960700_B20","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.3389\/fimmu.2020.01103","article-title":"Intestinal delivery of proinsulin and IL-10 via Lactococcus lactis combined with low-dose anti-CD3 restores tolerance outside the window of acute type 1 diabetes diagnosis","volume":"11","author":"Cook","year":"2020","journal-title":"Front Immunol"},{"key":"2023092018510960700_B21","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/nrm3313","article-title":"MicroRNAs in metabolism and metabolic disorders","volume":"13","author":"Rottiers","year":"2012","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2023092018510960700_B22","doi-asserted-by":"crossref","first-page":"6897","DOI":"10.1038\/s41598-017-07172-1","article-title":"Regulatory T-cells from pancreatic lymph nodes of patients with type-1 diabetes express increased levels of microRNA miR-125a-5p that limits CCR2 expression","volume":"7","author":"Sebastiani","year":"2017","journal-title":"Sci Rep"},{"key":"2023092018510960700_B23","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41580-018-0045-7","article-title":"Regulation of microRNA function in animals","volume":"20","author":"Gebert","year":"2019","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2023092018510960700_B24","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41580-018-0059-1","article-title":"Regulation of microRNA biogenesis and its crosstalk with other cellular pathways","volume":"20","author":"Treiber","year":"2019","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2023092018510960700_B25","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/ncb1596","article-title":"Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells","volume":"9","author":"Valadi","year":"2007","journal-title":"Nat Cell Biol"},{"key":"2023092018510960700_B26","doi-asserted-by":"crossref","first-page":"682948","DOI":"10.3389\/fimmu.2021.682948","article-title":"Extracellular vesicles in immune system regulation and type 1 diabetes: cell-to-cell communication mediators, disease biomarkers, and promising therapeutic tools","volume":"12","author":"Grieco","year":"2021","journal-title":"Front Immunol"},{"key":"2023092018510960700_B27","doi-asserted-by":"crossref","first-page":"5003","DOI":"10.1073\/pnas.1019055108","article-title":"Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma","volume":"108","author":"Arroyo","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"2023092018510960700_B28","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s40618-017-0611-4","article-title":"Circulating microRNAs and diabetes mellitus: a novel tool for disease prediction, diagnosis, and staging?","volume":"40","author":"Sebastiani","year":"2017","journal-title":"J Endocrinol Invest"},{"key":"2023092018510960700_B29","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/MED.0000000000000420","article-title":"MicroRNAs: markers of \u03b2-cell stress and autoimmunity","volume":"25","author":"Dotta","year":"2018","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"2023092018510960700_B30","doi-asserted-by":"crossref","first-page":"e89656","DOI":"10.1172\/jci.insight.89656","article-title":"Profiling of circulating microRNAs in children with recent onset of type 1 diabetes","volume":"2","author":"Erener","year":"2017","journal-title":"JCI Insight"},{"key":"2023092018510960700_B31","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1007\/s00125-019-05026-1","article-title":"miR-409-3p is reduced in plasma and islet immune infiltrates of NOD diabetic mice and is differentially expressed in people with type 1 diabetes","volume":"63","author":"Ventriglia","year":"2020","journal-title":"Diabetologia"},{"key":"2023092018510960700_B32","doi-asserted-by":"crossref","first-page":"5245","DOI":"10.1158\/0008-5472.CAN-04-0496","article-title":"Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets","volume":"64","author":"Andersen","year":"2004","journal-title":"Cancer Res"},{"key":"2023092018510960700_B33","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1038\/nmeth.4380","article-title":"Simultaneous epitope and transcriptome measurement in single cells","volume":"14","author":"Stoeckius","year":"2017","journal-title":"Nat Methods"},{"key":"2023092018510960700_B34","doi-asserted-by":"crossref","first-page":"3885","DOI":"10.2337\/db15-0449","article-title":"Acute versus progressive onset of diabetes in NOD mice: potential implications for therapeutic interventions in type 1 diabetes","volume":"64","author":"Mathews","year":"2015","journal-title":"Diabetes"},{"key":"2023092018510960700_B35","doi-asserted-by":"crossref","first-page":"100","DOI":"10.2337\/db16-0592","article-title":"MicroRNAs miR-23a-3p, miR-23b-3p, and miR-149-5p regulate the expression of proapoptotic BH3-only proteins DP5 and PUMA in human pancreatic \u03b2-Cells","volume":"66","author":"Grieco","year":"2017","journal-title":"Diabetes"},{"key":"2023092018510960700_B36","doi-asserted-by":"crossref","first-page":"5903","DOI":"10.3390\/ijms20235903","article-title":"Profiling of RNAs from human islet-derived exosomes in a model of type 1 diabetes","volume":"20","author":"Krishnan","year":"2019","journal-title":"Int J Mol Sci"},{"key":"2023092018510960700_B37","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/JLB.1RU1219-504RR","article-title":"Transcriptional regulation of neutrophil differentiation and function during inflammation","volume":"107","author":"Ai","year":"2020","journal-title":"J Leukoc Biol"},{"key":"2023092018510960700_B38","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1002\/JLB.3A0820-207R","article-title":"Neutrophil recruitment by chemokines Cxcl1\/KC and Cxcl2\/MIP2: role of Cxcr2 activation and glycosaminoglycan interactions","volume":"109","author":"Sawant","year":"2021","journal-title":"J Leukoc Biol"},{"key":"2023092018510960700_B39","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1365-2249.2010.04153.x","article-title":"Developing combination immunotherapies for type 1 diabetes: recommendations from the ITN-JDRF Type 1 Diabetes Combination Therapy Assessment Group","volume":"160","author":"Matthews","year":"2010","journal-title":"Clin Exp Immunol"},{"key":"2023092018510960700_B40","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S2213-8587(21)00044-9","article-title":"Combination therapy in recent-onset type 1 diabetes","volume":"9","author":"Long","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2023092018510960700_B41","first-page":"115","article-title":"AG019. ActoBiotics as monotherapy or in association with teplizumab in recent-onset type 1 diabetes was safe and demonstrated encouraging metabolic and immunological effects","volume":"64","author":"Mathieu","year":"2021","journal-title":"Diabetologia"},{"key":"2023092018510960700_B42","doi-asserted-by":"crossref","first-page":"100606","DOI":"10.1016\/j.xpro.2021.100606","article-title":"Protocol to analyze circulating small non-coding RNAs by high-throughput RNA sequencing from human plasma samples","volume":"2","author":"Grieco","year":"2021","journal-title":"STAR Protoc"},{"key":"2023092018510960700_B43","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.canlet.2019.04.015","article-title":"MicroRNA-125 in immunity and cancer","volume":"454","author":"Wang","year":"2019","journal-title":"Cancer Lett"},{"key":"2023092018510960700_B44","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1756-8722-6-6","article-title":"Diverse functions of miR-125 family in different cell contexts","volume":"6","author":"Sun","year":"2013","journal-title":"J Hematol Oncol"},{"key":"2023092018510960700_B45","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1186\/s13063-022-06259-z","article-title":"INNODIA master protocol for the evaluation of investigational medicinal products in children, adolescents and adults with newly diagnosed type 1 diabetes","volume":"23","author":"Dunger","year":"2022","journal-title":"Trials"},{"key":"2023092018510960700_B46","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.3109\/10428190903221010","article-title":"Identification of a novel microRNA cluster miR-193b-365 in multiple myeloma","volume":"50","author":"Unno","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"2023092018510960700_B47","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/MOH.0000000000000008","article-title":"Neutrophils and type 1 autoimmune diabetes","volume":"21","author":"Battaglia","year":"2014","journal-title":"Curr Opin Hematol"},{"key":"2023092018510960700_B48","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1111\/jdi.12469","article-title":"Neutrophils in type 1 diabetes","volume":"7","author":"Huang","year":"2016","journal-title":"J Diabetes Investig"},{"key":"2023092018510960700_B49","doi-asserted-by":"crossref","first-page":"e3483","DOI":"10.1002\/dmrr.3483","article-title":"Neutrophils and their role in the aetiopathogenesis of type 1 and type 2 diabetes","volume":"38","author":"Giovenzana","year":"2022","journal-title":"Diabetes Metab Res Rev"},{"key":"2023092018510960700_B50","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.2337\/db12-1345","article-title":"Reduction of circulating neutrophils precedes and accompanies type 1 diabetes","volume":"62","author":"Valle","year":"2013","journal-title":"Diabetes"},{"key":"2023092018510960700_B51","doi-asserted-by":"crossref","first-page":"e122146","DOI":"10.1172\/jci.insight.122146","article-title":"Abnormal neutrophil signature in the blood and pancreas of presymptomatic and symptomatic type 1 diabetes","volume":"3","author":"Vecchio","year":"2018","journal-title":"JCI Insight"},{"key":"2023092018510960700_B52","doi-asserted-by":"crossref","first-page":"e153993","DOI":"10.1172\/jci.insight.153993","article-title":"Circulating platelet-neutrophil aggregates characterize the development of type 1 diabetes in humans and NOD mice","volume":"7","author":"Popp","year":"2022","journal-title":"JCI Insight"},{"key":"2023092018510960700_B53","doi-asserted-by":"crossref","first-page":"21401","DOI":"10.1074\/jbc.M110.198630","article-title":"miR-365, a novel negative regulator of interleukin-6 gene expression, is cooperatively regulated by Sp1 and NF-\u03baB","volume":"286","author":"Xu","year":"2011","journal-title":"J Biol Chem"}],"container-title":["Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.org\/diabetes\/diabetes\/article-pdf\/72\/10\/1470\/734624\/db220852.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.org\/diabetes\/diabetes\/article-pdf\/72\/10\/1470\/734624\/db220852.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T18:53:02Z","timestamp":1695235982000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article\/72\/10\/1470\/153435\/A-Plasma-miR-193b-365-Signature-Combined-With-Age"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,26]]},"references-count":53,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,7,26]]},"published-print":{"date-parts":[[2023,10,1]]}},"URL":"https:\/\/doi.org\/10.2337\/db22-0852","relation":{},"ISSN":["0012-1797"],"issn-type":[{"value":"0012-1797","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7,26]]}}}